CO6680645A2 - Inhibidores de oxadiazol de la producción de leucotrieno - Google Patents

Inhibidores de oxadiazol de la producción de leucotrieno

Info

Publication number
CO6680645A2
CO6680645A2 CO13031460A CO13031460A CO6680645A2 CO 6680645 A2 CO6680645 A2 CO 6680645A2 CO 13031460 A CO13031460 A CO 13031460A CO 13031460 A CO13031460 A CO 13031460A CO 6680645 A2 CO6680645 A2 CO 6680645A2
Authority
CO
Colombia
Prior art keywords
compounds
leukotriene production
oxadiazole
inhibitors
oxadiazole inhibitors
Prior art date
Application number
CO13031460A
Other languages
English (en)
Inventor
Alessandra Bartolozzi
Todd Bosanac
Zhidong Chen
Lombaert Stephane De
John D Huber
Ho Yin Lo
Pui Leng Loke
Weimin Liu
Tina Marie Morwick
Alan Olague
Doris Riether
Heather Tye
Lifen Wu
Renee M Zindell
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44511591&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6680645(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CO6680645A2 publication Critical patent/CO6680645A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere un compuesto de fórmula (I):o sales farmacéuticamente aceptables del mismo, en la que R-Rson como se definen en la presente memoria. La invención también se refiere a composiciones farmacéuticas que comprenden estos compuestos, a métodos para usar estos compuestos en el tratamiento de diversas enfermedades y trastornos, a procedimientos para preparar estos compuestos y a compuestos intermedios útiles en estos procedimientos.
CO13031460A 2010-08-16 2013-02-15 Inhibidores de oxadiazol de la producción de leucotrieno CO6680645A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37392510P 2010-08-16 2010-08-16
US201161492176P 2011-06-01 2011-06-01

Publications (1)

Publication Number Publication Date
CO6680645A2 true CO6680645A2 (es) 2013-05-31

Family

ID=44511591

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13031460A CO6680645A2 (es) 2010-08-16 2013-02-15 Inhibidores de oxadiazol de la producción de leucotrieno

Country Status (22)

Country Link
US (1) US8658661B2 (es)
EP (1) EP2606045B1 (es)
JP (1) JP5619284B2 (es)
KR (1) KR20130100105A (es)
CN (1) CN103180314A (es)
AP (1) AP2013006678A0 (es)
AR (1) AR082696A1 (es)
AU (1) AU2011292285A1 (es)
BR (1) BR112013003439A2 (es)
CA (1) CA2807364A1 (es)
CL (1) CL2013000455A1 (es)
CO (1) CO6680645A2 (es)
EA (1) EA201300250A1 (es)
EC (1) ECSP13012494A (es)
MX (1) MX2013001872A (es)
NZ (1) NZ605690A (es)
PE (1) PE20130751A1 (es)
SG (1) SG187549A1 (es)
TW (1) TW201238947A (es)
UY (1) UY33557A (es)
WO (1) WO2012024150A1 (es)
ZA (1) ZA201300238B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012024150A1 (en) 2010-08-16 2012-02-23 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production
US8580829B2 (en) * 2010-08-26 2013-11-12 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production
BR112013008638A2 (pt) * 2010-09-23 2016-06-21 Boehringer Ingelheim Int inibidores de oxadiazol de produção de leucotrieno
JP5828188B2 (ja) * 2010-09-23 2015-12-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン産生のオキサジアゾール阻害剤
EP2651930B1 (en) * 2010-12-16 2015-10-28 Boehringer Ingelheim International GmbH Biarylamide inhibitors of leukotriene production
EP2686291B1 (en) 2011-03-18 2016-11-30 Boehringer Ingelheim International GmbH Process for preparing carboxylic acids
WO2013116182A1 (en) * 2012-01-31 2013-08-08 Boehringer Ingelheim International Gmbh Heterocyclic compounds as inhibitors of leukotriene production
AR089853A1 (es) 2012-02-01 2014-09-24 Boehringer Ingelheim Int Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso
US9029592B2 (en) * 2012-02-09 2015-05-12 Boehringer Ingelheim International Gmbh Process for preparing carboxamidine compounds
EP2746279A1 (en) 2012-12-19 2014-06-25 Basf Se Fungicidal imidazolyl and triazolyl compounds
WO2014095381A1 (en) 2012-12-19 2014-06-26 Basf Se Fungicidal imidazolyl and triazolyl compounds
WO2014095249A1 (en) 2012-12-19 2014-06-26 Basf Se Fungicidal imidazolyl and triazolyl compounds
EP2746256A1 (en) 2012-12-19 2014-06-25 Basf Se Fungicidal imidazolyl and triazolyl compounds
EP2746277A1 (en) 2012-12-19 2014-06-25 Basf Se Fungicidal imidazolyl and triazolyl compounds
CN103724279B (zh) * 2014-01-20 2016-04-06 新发药业有限公司 一步成环制备2-甲基-4-氨基-5-氨基甲基嘧啶的便捷合成方法
US10562869B2 (en) 2014-03-17 2020-02-18 Remynd Nv Oxadiazole compounds

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3141019A (en) * 1964-07-14 Chaohj
GB1053825A (es) * 1963-03-22
JP2719742B2 (ja) * 1991-04-30 1998-02-25 株式会社大塚製薬工場 フェニルチアゾール誘導体
CA2294145A1 (en) * 1997-07-10 1999-01-21 Janssen Pharmaceutica N.V. Il-5 inhibiting 6-azauracil derivatives
EP0987265A1 (en) * 1998-09-18 2000-03-22 Janssen Pharmaceutica N.V. Interleukin-5 inhibiting 6-azauracil derivatives
HUP0202692A3 (en) 1999-08-06 2003-01-28 Janssen Pharmaceutica Nv Interleukin-5 inhibiting 6-azauracil derivatives, pharmaceutical compositions containing them and intermediates
US7319108B2 (en) 2004-01-25 2008-01-15 Sanofi-Aventis Deutschland Gmbh Aryl-substituted heterocycles, process for their preparation and their use as medicaments
EP1814877B1 (en) * 2004-10-18 2009-03-11 Merck & Co., Inc. Diphenyl substituted alkanes as flap inhibitors
EP2272848B1 (en) * 2005-08-10 2012-12-26 Glaxosmithkline LLC Xanthine derivatives as selective HM74A agonists
GB0516464D0 (en) * 2005-08-10 2005-09-14 Smithkline Beecham Corp Novel compounds
US20070219206A1 (en) * 2005-11-04 2007-09-20 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) * 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
JP2009533435A (ja) * 2006-04-11 2009-09-17 メルク エンド カムパニー インコーポレーテッド ジアリール置換アルカン
WO2007130499A2 (en) * 2006-05-01 2007-11-15 Virobay, Inc. Antiviral agents
US20080096900A1 (en) * 2006-06-26 2008-04-24 Amgen Inc. Methods for treating atherosclerosis
AU2007293373A1 (en) * 2006-09-01 2008-03-13 Merck Sharp & Dohme Corp. Inhibitors of 5 -lipoxygenase activating protein (FLAP)
FR2906866A1 (fr) * 2006-10-10 2008-04-11 Felix Ifrah Luminaire comprenant au moins un moyen d'eclairage dont l'activation s'effectue par l'emission d'un rayonnement lumineux
WO2008050200A1 (en) * 2006-10-24 2008-05-02 Pfizer Products Inc. Oxadiazole compounds as calcium channel antagonists
EP2148878A4 (en) 2007-04-20 2011-08-10 Merck Canada Inc NEW HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME-A-DELTA-9-DESATURASE
EP2170065A4 (en) 2007-06-20 2011-11-23 Merck Sharp & Dohme DIPHENYL SUBSTITUTED ALKANES
JP2011500563A (ja) 2007-10-10 2011-01-06 メルク・シャープ・エンド・ドーム・コーポレイション ジフェニル置換されたシクロアルカン
JP2012516885A (ja) * 2009-02-04 2012-07-26 ファイザー・インク ４−アミノ−７，８−ジヒドロピリド［４，３−ｄ］ピリミジン−５（６Ｈ）−オン誘導体
JP2013526544A (ja) 2010-05-12 2013-06-24 ヴァンダービルト ユニバーシティー 複素環スルホンｍＧｌｕＲ４アロステリック増強剤、組成物、および神経機能不全を治療する方法
WO2012024150A1 (en) 2010-08-16 2012-02-23 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production
US8580829B2 (en) 2010-08-26 2013-11-12 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production
JP5828188B2 (ja) 2010-09-23 2015-12-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン産生のオキサジアゾール阻害剤

Also Published As

Publication number Publication date
TW201238947A (en) 2012-10-01
CL2013000455A1 (es) 2013-05-03
KR20130100105A (ko) 2013-09-09
SG187549A1 (en) 2013-03-28
ZA201300238B (en) 2014-06-25
EP2606045B1 (en) 2016-01-06
CA2807364A1 (en) 2012-02-23
US20120220561A1 (en) 2012-08-30
EA201300250A1 (ru) 2013-08-30
ECSP13012494A (es) 2013-04-30
MX2013001872A (es) 2013-09-02
EP2606045A1 (en) 2013-06-26
JP5619284B2 (ja) 2014-11-05
UY33557A (es) 2012-03-30
WO2012024150A1 (en) 2012-02-23
CN103180314A (zh) 2013-06-26
JP2013534245A (ja) 2013-09-02
US8658661B2 (en) 2014-02-25
PE20130751A1 (es) 2013-06-21
NZ605690A (en) 2014-06-27
AP2013006678A0 (en) 2013-01-31
AU2011292285A1 (en) 2013-01-31
BR112013003439A2 (pt) 2019-09-24
AR082696A1 (es) 2012-12-26

Similar Documents

Publication Publication Date Title
CO6680645A2 (es) Inhibidores de oxadiazol de la producción de leucotrieno
UY39646A (es) Procedimiento para la preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
ECSP15012804A (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
UY35242A (es) Inhibidores de fosfatidilinositol 3-quinasa
CO6670589A2 (es) Compuestos para reducir la producción de beta-amiloide
MD20160078A2 (ro) Inhibitori ai Syk
UY32174A (es) Nuevos heterociclos sustituidos, composiciones farmaceuticas conteniendolos, procedimientos de preparacion y aplicaciones
EA201490774A1 (ru) Новые производные оксазина и их применение при лечении заболевания
EA201490724A1 (ru) Замещенные соединения тетрагидроизохинолина в качестве ингибиторов фактора xia
CO6771439A2 (es) Inhibidores de benzodioxano de la producción de leucotrieno
BR112012008147A2 (pt) compostos heteroarílicos como inibidores da quinase
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
CU20130126A7 (es) Inhibidores sustituidos de acetil-coa carboxilasa
EA201270492A1 (ru) Соединения для лечения дислипидемии и связанных с ней заболеваний
EA201490272A1 (ru) Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы
DOP2016000276A (es) 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
UY35551A (es) Derivados heteroarilos como inhibidores de aldosterona sintasa
CO6710902A2 (es) Inhibidores de oxadiazol de la producción de leucotrienos
MX2015008187A (es) Inhibidores de alk deuterados.
PH12017500595B1 (en) Aldosterone synthase inhibitors
BR112017000584A2 (pt) inibidores da aldosterona sintase
PH12014501943A1 (en) Novel compounds for the treatment of dyslipidemia and related diseases
BR112015004292A2 (pt) compostos do tipo indol-amida como inibidores de beta-amiloide
TN2013000052A1 (en) Oxadiazole inhibitors of leukotriene production
TN2013000122A1 (en) Oxadiazole inhibitors of leukotriene production

Legal Events

Date Code Title Description
FC Application refused